Why Did AIM Stock Jump 60% Today?

• While the patent was granted in September 2025, it had to pass a 6-month opposition period.
• The patent, which expires in 2039, spans multiple cancer types, including pancreatic cancer.
• AIM is seeking an orphan drug designation in Japan for its treatment.

Shares of AIM ImmunoTech Inc (AIM) gave up some of its pre-market gains and was up more than 60% on Wednesday, after the company said that a Japanese patent using its proprietary Ampligen in combination with checkpoint inhibitors to treat cancer was fully approved in the country.

While the patent was granted in September 2025, it had to pass a 6-month opposition period, AIM said. The patent, which expires in 2039, spans multiple cancer types, including pancreatic cancer. The company holds similar patents in the U.S. and the Netherlands.

AIM, which already holds orphan drug designations for pancreatic cancer in the U.S. and Europe, also plans to seek a similar designation in Japan.

DURIPANC Study Update

Earlier this month, AIM ImmunoTech partnered with Thermo Fisher Scientific’s PPD clinical research unit to design a planned Phase 3 trial of Ampligen for late-stage pancreatic cancer. 

The company also highlighted encouraging results from its ongoing DURIPANC study, including improvements in progression-free and overall survival. The trial is being conducted in collaboration with AstraZeneca and Erasmus Medical Center.

"Based on the success so far, as well as anticipated final patient enrollment later this year, we believe it is now time to start mapping out the next steps for AIM’s development of Ampligen as a therapy for pancreatic cancer," said CEO Thomas K. Equels.

"AIM’s scientific team will work closely with Thermo Fisher’s experts in the design of a Phase 3 study and we look forward to their expertise and guidance in this critical endeavor."

How Did Stocktwits Users React?

Retail sentiment flipped to 'extremely bullish' from 'bearish' a day earlier, amid 'extremely high' message volumes.

One user said the RSI has cooled and its time for the next leg of the rally.

Year-to-date, the stock has climbed 1%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.